2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16
2007
Resistência e refratariedade no transtorno obsessivo-compulsivo
Ferrão Y, Diniz J, Lopes A, Shavitt R, Greenberg B, Miguel E. Resistência e refratariedade no transtorno obsessivo-compulsivo. Brazilian Journal Of Psychiatry 2007, 29: s66-s76. PMID: 18172943, DOI: 10.1590/s1516-44462006005000059.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsAntipsychotic AgentsBehavior TherapyClinical Trials as TopicCombined Modality TherapyDrug ResistanceDrug ToleranceFamily RelationsHumansMeta-Analysis as TopicObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychotherapySelective Serotonin Reuptake InhibitorsConceptsObsessive-compulsive disorder patientsObsessive-compulsive disorderTherapeutic alternativeDisorder patientsConventional treatmentEffective therapeutic alternativeCompulsive disorder patientsAvailable treatmentsTreatment responseClinical challengeTreatment resistanceSymptom remissionAdequate treatmentPatient sufferingPatientsCurrent conceptsRemissionMore studiesTreatmentDisordersSignificant numberLiterature reviewUnanswered questionsExtrinsic factors
2005
Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder
Fontenelle L, Mendlowicz M, Miguel E, Versiani M. Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder. The World Journal Of Biological Psychiatry 2005, 6: 57-59. PMID: 16097406, DOI: 10.1080/15622970510029740.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderSRI-resistant obsessive compulsive disorderResistant obsessive-compulsive disorderCombination of citalopramFirst-line treatmentAdequate trialReuptake inhibitorsCompulsive disorderPatientsCitalopramDisordersFuture studiesTrials